BENDAMUSTINE COMBINATION THERAPY IS ASSOCIATED WITH POOR OUTCOME IN MYELOMA PATIENTS WITH ADVERSE CYTOGENETICS WHO RELAPSED FOLLOWING A PROTEASOME INHIBITOR AND ARE REFRACTORY OR INTOLERANT TO IMIDS
HAEMATOLOGICA(2012)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要